...
首页> 外文期刊>Gene: An International Journal Focusing on Gene Cloning and Gene Structure and Function >A novel mutation identified in PKHD1 by targeted exome sequencing: Guiding prenatal diagnosis for an ARPKD family
【24h】

A novel mutation identified in PKHD1 by targeted exome sequencing: Guiding prenatal diagnosis for an ARPKD family

机译:通过靶向外显子组测序在PKHD1中鉴定出一种新突变:为ARPKD家族提供产前诊断指导

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Autosomal recessive polycystic kidney disease (ARPKD) is a rare hereditary renal cystic disease involving multiple organs, mainly the kidney and liver. Parents who had an affected child with ARPKD are in strong demand for an early and reliable prenatal diagnosis to guide the future pregnancies. Here we provide an example of prenatal diagnosis of an ARPKD family where traditional antenatal ultrasound examinations failed to produce conclusive results till 26th week of gestation. Compound heterozygous mutations c.274C>T (p.Arg92Trp) and c.9059T>C (p.Leu3020Pro) were identified using targeted exome sequencing in the patient and confirmed by Sanger sequencing. Further, the mother and father were revealed to be carriers of heterozygous c.274C>T and c.9059T>C mutations, respectively. Molecular prenatal diagnosis was performed for the current pregnancy by direct sequencing plus linkage analysis. Two mutations identified in the patient were both found in the fetus. In conclusion, compound heterozygous PKHD1 mutations were elucidated to be the molecular basis of the patient with ARPKD. The newly identified c.9059T>C mutation in the patient expands mutation spectrum in PKHD1 gene. For those ultrasound failed to provide clear diagnosis, we propose the new prenatal diagnosis procedure: first, screening underlying mutations in PKHD1 gene in the proband by targeted exome sequencing; then detecting causative mutations by direct sequencing in the fetal DNA and confirming results by linkage analysis.
机译:常染色体隐性隐性多囊肾疾病(ARPKD)是一种罕见的遗传性肾囊性疾病,涉及多个器官,主要是肾脏和肝脏。对患有ARPKD患病孩子的父母强烈要求进行早期可靠的产前诊断,以指导将来的怀孕。在这里,我们提供了一个ARPKD家族的产前诊断示例,在该示例中,传统的产前超声检查直到妊娠26周仍未得出结论。使用患者中的靶向外显子组测序鉴定了复合杂合突变c.274C> T(p.Arg92Trp)和c.9059T> C(p.Leu3020Pro),并通过Sanger测序进行了确认。此外,母亲和父亲分别是杂合的c.274C> T和c.9059T> C突变的携带者。通过直接测序加连锁分析对当前妊娠进行了分子产前诊断。在胎儿中发现了在患者中鉴定出的两个突变。总之,已阐明复合杂合性PKHD1突变是ARPKD患者的分子基础。患者中新发现的c.9059T> C突变扩大了PKHD1基因的突变谱。对于那些未能提供明确诊断的超声,我们提出了新的产前诊断程序:首先,通过靶向外显子组测序筛查先证者中PKHD1基因的潜在突变;然后通过直接测序胎儿DNA来检测致病突变,并通过连锁分析确认结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号